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Introduction
Th e overall aims of neuromonitoring are to: 1)  identify 
worsening neurological function and secondary cerebral 
insults that may beneﬁ t from speciﬁ c treatment(s); 
2) improve pathophysiological understanding of cerebral 
disease in critical illness; 3)  provide clear physiological 
data to guide and individualize therapy; 4)  assist with 
prog nostication. In this article, we will outline the neuro-
monitoring techniques currently in use in critically ill 
patients and suggest how they should be best applied to 
help us care for such patients. We will focus on clinically 
available techniques and not discuss new approaches that 
are still largely in the research stage of development.
Pathophysiology of acute brain injury
Th e pathophysiology of acute brain injury is complex and 
can involve several secondary pathological cascades that 
contribute to aggravate neuronal injury (Figure  1). Th e 
clinical rationale for neuromonitoring is to tailor therapy 
to patient-speciﬁ c pathophysiology rather than to pre-
deﬁ ned thresholds or targets. It is thus important to 
brieﬂ y review some basic aspects of brain physiology to 
help understand the techniques and applications of 
neuromonitoring.
Cerebral metabolism
Th e human brain constitutes 2% of body weight, yet the 
energy-consuming processes that enable adequate brain 
function account for about 25% of total body energy 
expenditure and 20% of the oxygen consumption of the 
whole organism. Glucose is the main energy substrate of 
the brain and, given the low glycogen stores in the brain, 
brain glucose levels are highly dependent on blood 
glucose. Transport of glucose from the systemic circu-
lation to the brain is a tightly regulated process mediated 
by specialized cell membrane glucose transporters 
(GLUT). Experimental and human studies show evidence 
of ﬂ ow-metabolism uncoupling and increased glucose 
utilization after acute brain injury (‘cerebral hyper-
glycolysis’). Importantly, this can occur in the absence of 
low cerebral blood ﬂ ow (CBF) and cerebral ischemia and 
may lead to a state of reduced availability of the main 
energy substrate (glucose) with a subsequent risk of 
cerebral energy dysfunction [1,2]. However, hyperglyco-
lysis also results in increased processing of glucose to 
pyruvate by astrocytes and conversion to lactate. 
Endogenous lactate, released in the extracellular space, 
can in turn be transferred, via speciﬁ c monocarboxylate 
transporters, to neurons (a process known as the ‘astro-
cyte-neuron lactate shuttle’) [3]. Brain lactate may thus 
be used as an alternative aerobic energy substrate to glucose 
[4]. Indeed, studies in subarachnoid hemorrhage (SAH) 
patients suggest that a pattern of increased cerebral hyper-
glycolytic lactate is associated with better outcome [5].
Cerebral blood fl ow, oxygen delivery and ischemia
Cerebral ischemia is a frequent cause of secondary brain 
injury [6]. In normal conditions, reduced systemic 
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pressure triggers an active vasodilatory response that 
keeps cerebral blood ﬂ ow (CBF) constant over a wide 
range of mean arterial pressures (MAPs), thereby pre-
vent ing brain hypoperfusion (cerebral pressure autoregu-
la tion) [7]. In brain-injured patients, cerebrovascular 
reactivity may be impaired, and a decrease in MAP or 
cerebral perfusion pressure (CPP) may thus translate into 
reduced CBF and secondary ischemia [8].
Cerebral oxygen utilization is proportional to the 
product of CBF and the arterio-venous diﬀ erence in 
oxygen content [9]. Mechanisms other than perfusion-
limited ischemia (microvascular collapse, endothelial 
swelling, perivascular edema) may increase the diﬀ usion 
gradient for oxygen between venous blood and brain 
tissue (PvO2-PbtO2), reduce cellular oxygen delivery and 
attenuate the ability of the brain to increase oxygen 
extraction fraction in response to reduced CBF [10].
Neurological examination of the ICU patient
Clinical neurological examination is a fundamental com-
po nent of neuromonitoring and should take into account 
the eﬀ ects of sedative drugs, which may markedly 
inﬂ uence neurological responses. Th e degree of aware-
ness should ﬁ rst be assessed. Clinical assessment is based 
mainly on evaluating eye and motor responses to verbal 
orders and noxious stimuli. Th e depth of coma can be 
evaluated by the Glasgow Coma Scale (GCS) [11] or the 
Full Outline of UnResponsiveness (FOUR) score [12], 
which includes assessment of the pupillary light and 
corneal reﬂ exes and of the breathing pattern. Delirium is 
a ﬂ uctuating state characterized by altered attention, 
spatio-temporal disorientation, disorganized thinking 
and alteration of awareness. Delirious patients can be 
hypo active, hyperactive or both alternately. Th e Con fusion 
Assessment Method for the ICU (CAM-ICU) [13] or the 
ICU Delirium Screening Checklist (ICU DSC) [14] can 
be used to assess the presence and degree of delirium.
Neurological examination should then assess for neck 
stiﬀ ness, motor responses, plantar and deep tendon 
reﬂ exes and cranial nerve functions. Th e presence of 
focal neurological signs should prompt brain imaging, 
which should also be considered, along with an electro-
encephalogram (EEG), if there is no obvious cause for 
delirium or coma.
Monitoring techniques
Intracranial pressure
Elevated intracranial pressure (ICP; >20 mmHg) is asso-
ciated with increased mortality after acute traumatic 
brain injury (TBI) [15]. Th e most recent Brain Trauma 
Foundation guide lines [16] recommend (level II 
evidence) that ICP should be monitored in all salvageable 
patients with severe TBI (GCS score of 3 to 8 after 
resuscitation) and an abnormal head CT scan.
ICP monitoring is also used in non-traumatic neuro-
logical disorders, such as SAH, and to a lesser extent in 
brain tumors, infarctions, intracerebral hemorrhage, and 
infections. After SAH, external ventricular drainage is 
recommended in patients with higher World Federation 
of Neurological Societies (WFNS) scale scores or acute 
hydrocephalus [17], to monitor ICP and to drain cerebro-
spinal ﬂ uid (CSF) for ICP control. In spontaneous intra-
cerebral hemorrhage, ICP monitoring is seldom used, but 
recent guidelines [18] suggest that in patients with a GCS 
score of <8, those with clinical evidence of transtentorial 
hernia tion, or those with intraventricular hemorrhage or 
hydrocephalus, ICP monitoring and treatment may be 
considered (class IIb; level of evidence: C).
ICP is a function of intracranial content: some content 
is easy to detect and correct, such as an expanding 
contusion, while others are more diﬃ  cult - for example, 
in cases of diﬀ use cerebral swelling, which may indicate 
vasodilation or edema. Th e volume-pressure curve, 
which describes ICP changes to corresponding increases 
in volume, has an exponential shape: as long as com-
pensatory mechanisms can be used (that is, displacement 
of CSF from the supratentorial space into the spinal sac), 
ICP will remain constant despite the volume increase. 
When compensatory capabilities are exceeded, ICP rises 
sharply. Attempts have been made to identify loss of 
compensation using ICP waveform analysis: the normal 
ICP waveform has three components (P1 > P2 > P3), but 
is altered when pressure increases, with an increase in 
the P2 component compared to P1 (Figure  2); the ICP 
pulse amplitude (diﬀ erence between systolic and diastolic 
values) also tends to increase [19]. However, this feature 
depends on the CPP and on the physical properties of the 
measuring system, and so should be used with caution.
Figure 1. Some of the pathological cascades contributing 
to aggravate neuronal injury after acute brain injury. Initial 
mechanisms, such as excitotoxicity and mitochondrial dysfunction, 
initiate damage in the very early minutes/hours; other factors, such as 
energy dysfunction, edema, and infl ammation come into play later in 
the process. CBF, cerebral blood fl ow.
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Although non-invasive evaluation of ICP is possible 
using the transcranial Doppler (TCD)-derived pulsatility 
index [20] or optic nerve sonography [21], the only 
methods for continuous on-line monitoring of ICP 
remain invasive. Intra-ventricular devices have long been 
considered the ‘gold standard’; however, intra-paren-
chymal pressure monitoring provides equivalent pressure 
measurements [22]. Intraventricular probes are particu-
larly useful when CSF drainage is desirable.
ICP management should also take CPP into account 
(Figure 3). Th erapies to reduce intracranial hypertension 
that also may reduce arterial pressure and CPP (for 
example, barbiturates) require careful titration to preserve 
adequate cerebral perfusion.
Cerebral blood fl ow
Direct, continuous measurement of regional CBF is now 
feasible using a thermal diﬀ usion probe (TDP; Hemedex® 
Cambridge, Massachusetts, USA) inserted into the brain 
parenchyma. Th e sensor at the tip provides a quantitative 
measure in the volume of tissue surrounding the sensor. 
Th e TDP technique showed good agreement with CBF 
measured by xenon-CT [23].
Correct and stable positioning of regional CBF probes 
with a skull bolt is crucial and a CT-scan should be 
performed to verify correct placement. Precise quanti-
ﬁ cation of regional CBF using a TDP is dependent on the 
presence of a stable temperature and may be altered in 
conditions of hyperthermia or rapid ﬂ uctuation in a 
patient’s temperature.
In patients with SAH, Muench and colleagues [24] used 
TDP monitoring to guide medical therapy for delayed 
cerebral ischemia, and demonstrated that increasing 
blood pressure with vasopressors was the only inter-
vention that improved CBF and PbtO2; hypervolemia and 
hemo dilu tion had only marginal eﬀ ects at best. Hence, 
normo volemia and MAP/CPP augmentation are increas-
ingly used instead of ‘triple-H’ therapy in these patients. 
TDP monitoring may also guide CPP manage ment after 
TBI [25]. TDP data are currently limited to small single-
center studies and larger trials are needed to conﬁ rm the 
validity and use of this technique.
Transcranial Doppler
Direct measurement of blood ﬂ ow in the brain arteries 
would be of value in all cases of brain damage. Using an 
ultrasound probe, ﬂ ow velocity (rather than ﬂ ow itself ) 
can be measured in the main arteries of the base of the 
brain. TCD combines ultrasound and the Doppler 
principle to represent erythrocyte ﬂ ow in the basal 
cerebral arteries. In some 10% of patients, transtemporal 
insonation is not feasible because of anatomical barriers. 
When cerebrovascular resistance increases - for example, 
in vasospasm of the middle cerebral artery - systolic TCD 
velocity increases, whereas diastolic velocity decreases, 
leading to a clear increase in the pulsatility index (the 
ratio of the diﬀ erence between systolic and diastolic ﬂ ow 
to diastolic ﬂ ow). For this reason, TCD is often used to 
monitor the time course of vasospasm after SAH [26]. 
However, correct interpretation of the pulsatility index is 
complex, because it depends not only on cerebrovascular 
resistance, but also on several systemic and cerebral 
variables [27].
TCD has also been used to assess cerebrovascular 
autoregulation in TBI and SAH patients [7]. Flow velocity 
responses to spontaneous or induced (with vasopressors) 
changes in CPP may quantify the status of static pressure 
autoregulation; autoregulation estimated by TCD in the 
middle cerebral artery correlated with autoregulation 
studied by positron emission tomography in TBI patients 
[28].
Th e main advantage of TCD is that it is non-invasive 
and can be carried out at the bedside. However, the 
quality of the TCD signal is operator-dependent and 
correct interpretation requires training. TCD signals may 
also vary over time with temperature, arterial carbon 
Figure 2. Intracranial pressure curve in conditions of normal and reduced compliance. Valuable information on intracranial buff ering 
mechanisms can be extracted from the shape of the curves: when all normal components (peaks) of the intracranial pressure (ICP) curve are clearly 
evident (left panel), the intracranial system is behaving normally and small increases in volume can still be compensated for. However, when a P2-
predominant pattern is displayed (right panel), the intracranial system is less compliant and compensatory abilities are reduced.
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dioxide tension (PaCO2 and, in some series, correlation 
with actual CBF measure ments was disappointing [29].
Microcirculation
Microcirculatory alterations play a key role in the patho-
genesis of organ dysfunction. Brain endothelial cells help 
regulate vessel diameter and permeability [30], contri buting 
to coupling of ﬂ ow to metabolism [31]. Unfor tu nately, it 
is still not possible to visualize the brain microcirculation 
in clinical practice without direct expo sure of the cerebral 
cortex after craniectomy and data on microvascular 
abnormalities in humans are limited.
Direct evaluation of the brain microcirculation can be 
performed using sidestream dark ﬁ eld imaging and 
Figure 3. Intracranial pressure (ICP), mean arterial pressure (MAP), and cerebral perfusion pressure (CPP) in a patient with traumatic brain 
injury undergoing bronchoscopy under general anesthesia with myorelaxants. ICP increased to 45 mmHg and CPP decreased concomitantly 
to 40 mmHg. Broncoscopy was stopped, further sedation given and manual hyperventilation administered briefl y. ICP and CPP returned to normal 
levels.
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intra vital microscopy [32]. Th ese methods allow con-
tinuous and in vivo observation of the microcirculation at 
high resolution as well as evaluation of vessel size, 
number, density and ﬂ ow. Although intravital microscopy 
is still considered the gold standard, it is not suitable for 
human use. Th e sidestream dark ﬁ eld technique can be 
applied on exposed cortical areas during craniectomy but 
care must be taken to limit pressure artifacts and 
minimize the risk of infection [33]. In patients with 
stroke from middle cerebral artery occlusion who under-
went decom pressive craniectomy, brain microcirculatory 
density and ﬂ ow were signiﬁ cantly altered when com-
pared to control patients [34]. Similarly, altered micro-
vascular reactivity has been demonstrated in patients 
with SAH [35].
Brain tissue oxygen monitoring
Several techniques can be used to measure brain 
oxygena tion, the most common in the ICU being jugular 
venous bulb oximetry and direct PbtO2 measurement. 
Near infra-red spectroscopy has also been used for this 
purpose.
Jugular venous bulb oximetry
Th is technique requires placement of a catheter into the 
jugular bulb. Th e arterio-jugular diﬀ erence in oxygen 
content (AJDO2) is proportional to CBF and inversely 
proportional to oxygen consumption (cerebral metabolic 
rate for oxygen, CMRO2) and is often used as a global 
measure of adequate perfusion. Proper positioning of the 
probe in the jugular bulb is crucial, since blood draining 
from extra-cerebral structures, such as the neck and face, 
can contaminate the lower portions of the jugular vein.
Under most conditions in which arterial hemoglobin 
saturation is constant, just the jugular oxygen saturation 
(SjO2) is measured. Th is measurement can be performed 
by intermittent sampling, or continuously using ﬁ ber-
optic probes. Normal values for SjO2 in patients without 
brain damage are about 57% (95% conﬁ dence interval 52 
to 62%) [36]. In the early hours after trauma, low SjO2 
values have been detected, especially in the most severe 
cases [37]. Severe and frequent SjO2 desaturations are 
associated with worse outcome in TBI patients [38].
Because of the anatomy of the cerebral circulation, SjO2 
is an average indicator and a large volume of brain must 
be underperfused for an abnormality to be detected. 
Two-thirds of the blood ﬂ owing in each jugular vein 
comes from the ipsilateral and one-third from the 
contralateral hemisphere [39]; focal areas of mismatch 
between ﬂ ow/metabolism can, therefore, be missed by 
this global measurement [40]. Additionally, SjO2 values in 
one jugular vein may diﬀ er from values in the other [41]. 
Despite these limitations, intermittent SjO2 sampling is a 
cheap and relatively easy tool for estimating adequacy of 
ﬂ ow and metabolism, particularly when CBF is manipu-
lated - for example, when using hyperventilation.
Direct PbtO2 measurement
Direct PbtO2 monitors are the most common technique 
used in the ICU to assess cerebral oxygenation. Probe 
positioning is crucial: usually inserted in the white 
matter, readings are dependent, in part, on proximity to 
intracranial pathology [42]. For example, if close to a 
contusion, values may be reduced and this should be 
considered when making management decisions. When 
the PbtO2 probe is in what appears to be normal white 
matter on CT, then the reading, although local in nature, 
provides a reasonable estimate of global brain oxygenation.
PbtO2 is not a ‘surrogate’ for ischemia or CBF, because 
it varies not only with CBF (and factors that regulate it - 
for example, CO2 and MAP) but also with changes in 
arterial oxygen tension (PaO2) among many other factors. 
PbtO2 is, therefore, more a marker of the balance between 
regional oxygen supply and cellular oxygen consumption 
[9].
Monitoring PbtO2 has been validated against ﬁ beroptic 
SjO2 monitoring, xenon-enhanced CT scanning, and 
SPECT. Th reshold values vary slightly depending on what 
type of PbtO2 monitor is used but values <20 mmHg are 
considered worth treating and values <15 mmHg indicate 
brain hypoxia or ischemia [43,44]. Decreases in PbtO2 
have been associated with independent chemical markers 
of brain ischemia in microdialysis studies [45]. Th e 
number, duration, and intensity of brain hypoxic episodes 
(PbtO2 <15 mmHg) and any PbtO2 values ≤5 mmHg are 
associated with poor outcome after TBI [46,47]. Episodes 
of brain hypoxia are common and may occur even when 
ICP and CPP are normal [48]. Th e exact relationship with 
outcome may, however, vary according to whether the 
probe is positioned in normal white matter, the 
penumbra or in a contusion [42,49]. Monitoring of PbtO2 
can be used in combination with other intra-parenchymal 
monitors, mainly ICP and cerebral microdialysis. Clinical 
studies suggest that therapy based on information from 
both an ICP and a PbtO2 monitor may be associated with 
better outcomes than that based on ICP monitoring 
alone [50].
Near infra-red spectroscopy
Oxyhemoglobin, deoxyhemoglobin, and oxidized cyto-
chrome oxidase absorb speciﬁ c portions of the light 
spectra. When a tissue layer is illuminated with a source 
of light in the near infra-red wavelength, the attenuation 
of the light signal is correlated to the relative proportions 
of oxyhemoglobin and deoxyhemoglobin (HbO2/Hb) and 
oxidized cytochrome oxidase in the tissue. Using appro-
priate calculations, an estimate of tissue oxygenation can, 
therefore, be made non-invasively and continuously. 
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Near infra-red spectroscopy has been used in TBI [51] 
and SAH [52], with ambiguous results. Th e technique has 
major limitations in adults: baseline normal values vary 
widely, extracranial contamination is a problem, and 
poor correlation with independent measurements of 
cerebral oxygenation has been reported frequently.
Microdialysis
Cerebral microdialysis (CMD) involves the insertion of a 
catheter tipped with a semi-permeable membrane 
(usually with a 20 kDa cutoﬀ ) in the brain parenchyma. 
Th e CMD catheter is constantly perfused, thereby allow-
ing regular sampling of the patient’s brain extracellular 
ﬂ uid [53]. CMD sampling is limited to the interstitial 
tissue area around the catheter, thus measuring regional 
brain metabolism. In clinical practice, a pattern of 
elevated lactate/pyruvate ratio and low glucose is con-
sidered as a warning sign for cerebral ischemia/hypoxia 
[54,55]. High lactate/pyruvate ratios in normoxic condi-
tions have been interpreted as markers of hyper glycolysis. 
Elevated glutamate is a marker of cellular dysfunction, 
for example, delayed cerebral ischemia in high-risk SAH 
patients [56]. Absolute CMD values are important, but 
trends over time may provide more useful information. 
Recently, CMD has been used to identify the ‘optimal’ 
threshold for blood glucose during insulin therapy [57], 
and when used in combination with PbtO2, CMD moni-
tor ing has potential clinical utility to target adequate 
values of MAP/CPP [58,59] and blood hemo globin 
concentration [60].
Biomarkers
Neurological biomarkers, quantitative indicators of brain 
dysfunction or damage, may be obtained via sampling of 
biological tissues (blood, CSF, brain interstitial ﬂ uid), 
electrophysiological recordings, or neuroimaging. For 
soluble biomarkers, modeling of extracerebral concen tra-
tion kinetics is complex and must account for passage 
across anatomical barriers into the bloodstream or CSF; 
serum levels of a marker may therefore correlate less 
closely with brain levels than with alterations in blood-
brain barrier integrity. An emerging body of work 
suggests that multi-marker panels may enhance sensi-
tivity and speciﬁ city for acute neurological injury [61,62]. 
Th ere is also considerable interest in genomic, proteomic 
and lipidomic proﬁ les.
Brain biomarkers are categorized according to their 
source as primarily neuronal, astroglial, or microglial. 
Here we brieﬂ y review the key biomarkers that have been 
tested clinically in acute neurological injury.
s-100β
Increased levels of this astroglial protein are associated 
with injury severity and are predictive of long-term death 
or severe disability in severe TBI [63,64], and following 
cardiac arrest [65] or aneurysmal SAH [66]. Although 
highly sensitive, the speciﬁ city of this marker for acute 
brain injury is generally low [67].
Glial fi brillary acidic protein
Glial ﬁ brillary acidic protein is associated with inter-
mediate ﬁ laments in astrocytes. Increased serum levels 
are observed following moderate and severe TBI [68], 
ischemic stroke [69], SAH [70], and cardiac arrest [71]. 
Serum glial ﬁ brillary acidic protein levels more accurately 
discriminate TBI outcomes than do levels of s-100β [72].
Neuron-specifi c enolase
Neuron-speciﬁ c enolase is an enzyme that is found in 
neurons, cells of neuroendocrine origin, erythrocytes and 
platelets. Increased serum neuron-speciﬁ c enolase has 
been observed in patients with ischemic stroke, TBI, 
SAH and after cardiac arrest [63,65,73]. Neuron-speciﬁ c 
enolase can help discriminate between favorable and 
unfavorable outcomes following severe TBI and cardiac 
arrest [63,65].
Tau
Tau is a neuronal protein that stabilizes microtubules, 
thereby promoting axonal transport. Signiﬁ cant eleva-
tions in tau have been observed in the CSF [74] and brain 
interstitial ﬂ uid [75] of patients with severe TBI. CSF tau 
protein is also elevated in patients with SAH, and is 
associated with neurological severity and outcome [76].
Amyloid β
Amyloid β is a peptide cleaved from neuronal and glial 
amyloid precursor protein. CSF amyloid β fragment 
levels are lower in TBI and in SAH patients than in 
control subjects, and lower levels are predictive of short-
term functional outcome [77]. Recently, amyloid β has 
been measured in brain interstitium [75,78].
Neurofi lament heavy chain
Elevated levels of NfH (neuroﬁ lament heavy chain), a 
neuronal protein that is integral to the axonal 
cytoskeleton, have been reported in the brain interstitial 
ﬂ uid of patients with severe TBI and are associated with 
physiological abnormalities and mortality [79]. CSF NfH 
is increased following SAH and hypertensive intra-
cerebral hemorrhage [80,81]. Serum concentrations of 
NfH do not reliably identify brain injury, perhaps because 
the large size of this molecule impedes passage through 
the blood-brain barrier.
Ubiquitin carboxy-terminal hydrolase L1
CSF levels of UCH-L1 (Ubiquitin carboxy-terminal 
hydro lase L1) are signiﬁ cantly elevated in severe TBI 
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patients and are associated with lower levels of 
conscious ness and worse six-month functional outcomes 
[82]. Serum levels of UCH-L1 are associated with TBI 
severity and survival [83].
Alpha II-spectrin
Alpha II-spectrin is a fundamental component of the 
neuronal cytoskeleton, which in the setting of injury is 
degraded into fragments referred to as spectrin break-
down products. CSF concentrations of these are elevated 
after TBI and correlate with the severity of injury and 
with six-month outcome [84]. Spectrin breakdown 
products are also detectable in serum and have diagnostic 
and prognostic value in children with TBI [85].
Electro-physiological measurements
Electroencephalogram
Th e classical indication for EEG is to detect and manage 
seizures, including status epilepticus. In critically ill 
patients, seizures are often non-convulsive and may 
aggravate brain injury [86]. Intermittent EEG is less 
sensitive than continuous EEG for detecting non-
convulsive status epilepticus [87]. Approximately 50% of 
non-convulsive seizures are recorded within the ﬁ rst 
60 minutes of EEG recording, but in some patients up to 
48 hours of monitoring may be required [88]. Over the 
past decade, a more advanced form of EEG, quantitative 
EEG (qEEG), has been developed, in which the raw EEG 
signal is converted into a digital form using fast Fourier 
transformation (compressed spectral array) (Figure 4).
Several groups have used qEEG to detect seizures and 
other causes of brain dysfunction, such as ischemia. In 
SAH patients, the percent alpha trend variability (PAV) 
decreased acutely with the onset of vasospasm-induced 
decreases in CBF and returned to normal with treatment 
and resolution of vasospasm [89]. More recently, Ratha-
krishnan and colleagues [90] reported that changes in α 
power could help to distinguish delayed cerebral ischemia 
from vasospasm after SAH. Th us, there appears to be 
good evidence for the use of qEEG to detect cerebral 
ischemia.
qEEG may also be used to monitor the depth of 
sedation in the ICU. Th e most commonly used modality 
is the ‘bispectral index’ (BIS) [91], an algorithm-derived 
number that approximates the degree of sedation-
induced EEG activity when patients are under general 
anesthesia. It ranges from 0 (brain dead) to 100 (normal 
brain function); a value of <60 indicates general anes-
thesia, and <30 indicates burst suppression.
Selected characteristics of raw EEG, such as the back-
ground rhythm and Synek scale, spontaneous variability 
and responsiveness stimulation, have been used to assist 
in estimating prognosis [92]. qEEG is more objective 
because it uses derived measures, and a larger amount of 
data that have been trended over time. Th e lack of PAV 
over time during the initial three days after severe TBI 
was associated with clinical outcome at 1 month [93] and 
6 months [94]. PAV trends are automatically created by 
modern EEG software, and can be useful in tracking 
improvement or lack of improvement in patients in real 
time (Figure 5). Caution is required when using PAV and 
other qEEG parameters, however, because they may be 
aﬀ ected by deep sedation.
Electrocorticography and spreading depression
Electrodes placed on the surface of the human cortex 
(electrocorticography), usually in proximity to damaged 
areas, can detect spontaneous waves of depolarization, 
which appear as spreading depression. Evidence is 
accumulating that these spreading depolarization waves 
cause an imbalance in energy consumption and delivery 
and may lead to secondary brain injury [95,96]. Spreading 
depression has been identiﬁ ed in TBI [97] and in patients 
with SAH [98] in whom the number of spreading 
depressions correlated signiﬁ cantly with the development 
of delayed cerebral ischemia even in the absence of 
vasospasm. Electrocorticography requires a craniotomy, 
but recent studies have suggested there may be correlates 
with human scalp direct and alternating current 
electroencephalography [99].
Evoked potentials
Somatosensory evoked potentials (SSEPs) are measured 
on the scalp as evoked EEG responses to an electrical 
stimulus applied typically to the median or tibial nerves. 
SSEPs are less aﬀ ected by pharmacological agents or 
hypothermia than is the EEG. Th e main variable used for 
prognosis is the cortical response, which usually occurs 
at 20 msec after the stimulus, and hence is called the N20 
peak. After cardiac arrest, bilateral absence of the N20 
SSEP is associated with persistent vegetative state or 
death in all patients [100,101]. SSEPs can be measured 
during periods of sedation and even hypothermia, but 
most clinicians wait for return of normothermia. Th ere is 
some concern about inter- and intra-observer variability 
in interpretation of SSEPs [102]. Th e use of so-called 
‘cognitive’ potentials, such as N70, has been suggested to 
improve the predictive value of poor prognosis of this 
test but this approach is not widely used [103].
Imaging
Computed tomography
CT is the imaging modality of choice in the initial 
evaluation of patients with TBI or when acute hemor-
rhage is suspected. It helps to rule out surgical masses, 
and to identify early signs of intracranial hypertension. 
Since hemorrhagic lesions or edema may evolve over the 
ﬁ rst hours after injury, a CT scan must be repeated 
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whenever there is clinical deterioration even if the initial 
imaging was apparently normal. Th e severity of TBI 
lesions may be classiﬁ ed using the Marshall [104] or 
Rotterdam [105] scales. New features, such as angioCT 
and CT perfusion, add important information to non-
contrast CT and are increasingly used in stroke and SAH 
evaluation.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) has great spatial 
resolution and, in patients with TBI, can identify patho-
logic abnormalities that are undetected or poorly charac-
terized with CT, such as traumatic axonal injury. Acute 
ischemic stroke can also be detected earlier using MRI 
than CT. MRI is multi-parametric and can provide 
anatomical detail and quantitative information on brain 
physiology and metabolism, also allowing neuronal 
activa tion to be mapped. MRI has the advantage over 
other radiological methods in that it does not require 
ionizing radiation. Challenges for MRI scanning of 
critically ill patients include: monitoring and resusci ta tion 
devices that are incompatible with the magnetic ﬁ eld, the 
need for sedation or even neuromuscular blockade to 
prevent movement artifacts, and the risks inherent to 
transport outside of the ICU environment.
Speciﬁ c MRI sequences can enhance the diagnostic 
and prognostic evaluation of patients with acute brain 
injury.
Diff usion weighted imaging
Reductions in the apparent diﬀ usion coeﬃ  cient (ADC), a 
marker of water diﬀ usion, are associated with acute 
tissue infarction in stroke and in cardiac arrest. Reduced 
ADC values have been noted in major gray matter and 
white matter structures after cardiac arrest and are 
predictive of six-month outcome [106].
Diff usion tensor imaging
Diﬀ usion tensor imaging evaluates the directional 
preference (anisotropy) of water diﬀ usion and allows 
quantitative assessments of white matter damage in 
patients with TBI. Th e magnitude of fractional anisotropy 
Figure 4. Transformation of raw electroencephalogram (EEG) into quantitative EEG (qEEG). The center top panel shows a 10 second segment 
of raw EEG. This EEG segment can be transformed using mathematical processing to separate the waves into major frequency bins with the height 
of each bin indicating the relative percentage (that is, power) of that frequency during the 10 second epoch (lower left panel). Each bandwidth 
can be trended on a minute by minute basis to create a variability histogram for that bandwidth for each channel (lower right panel). The alpha 
bandwidth variability trend is shown (lower center panel).
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change correlates with clinical TBI severity in the acute 
setting and with long-term outcomes [107,108].
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy measures tissue levels 
of selected neurometabolites and can provide important 
insight into TBI pathophysiology and natural history. It 
has been demonstrated that N-acetyl aspartate, a marker 
of neuronal integrity, is decreased in TBI, often in brain 
tissue that appears normal on cranial CT or on con-
ventional MRI. Brain N-acetyl aspartate levels are 
associated with worse clinical condition and are 
predictive of functional outcome following TBI [108].
Susceptibility weighted imaging
Susceptibility weighted imaging is highly sensitive to 
micro scopic hemorrhagic lesions associated with TBI, 
which are believed to represent a subtype of diﬀ use 
axonal injury. In children with diﬀ use axonal injury, the 
number and volume of hemorrhagic lesions seen with 
susceptibility weighted imaging correlates with neuro-
logical severity on initial presentation and with long-term 
cognitive impairment and functional disability [109].
Functional MRI
Functional MRI demonstrates that cortical-subcortical 
networks governing motor activity are signiﬁ cantly 
impaired following TBI [110].
Integration of variables
A single monitoring technique may not fully describe the 
complex pathophysiological changes in the brain and the 
concept of multimodality monitoring, the simultaneous 
digital recording of multiple parameters of brain func-
tion, has been introduced [111]. Multicenter collabora-
tions, such as BrainIT (Brain monitoring with Informa tion 
Technology collaborative network) [112], have demon-
strated that recording of many physiological variables 
across multiple patients is feasible and can provide new 
clinical insights [113]. Advanced statistical and 
Figure 5. Lack of variability over time of the percent alpha trend (PAV) is associated with poor clinical outcomes. The daily PAV scores are 
graphed for those brain injured patients who eventually had a good outcome (top panel) and those that had a poor outcome (bottom panel). The 
PAV scores tend to remain good or improve day by day in those patients with a good outcome, whereas they remain poor or worsen day by day in 
those patients with a bad outcome.
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mathe matical tools can be applied to the large volumes of 
data obtained with the aim of identifying patterns of 
brain injury and providing clinicians with easier 
identiﬁ cation of speciﬁ c targets [114]. Challenges in data 
integration and synchronization remain, but, ultimately, 
this concept should provide real-time, user-friendly 
advanced data analysis that, when applied at the bedside, 
could improve treatment.
Future trials
Neurological monitoring has developed rapidly over the 
past 25  years with widespread application of various 
monitors, but, although clinical studies suggest the 
physiological feasibility of this concept, there are still no 
published data from randomized trials to support that 
targeting any variables improves clinical outcome.
Neurocritical care research over the past 20 years has 
focused on the possibility that early pharmacological 
inter vention might improve outcome, which has deﬂ ected 
attention from trials designed to answer simple questions 
about the everyday management of acute brain injury 
patients, such as optimum hemoglobin transfusion 
thresholds, hyperventilation, and arterial pressure 
manage ment after hemorrhagic stroke, for example. 
More extensive availability and use of neuromonitoring 
technology should facilitate the development of large 
clinical trials networks to provide the infrastructure 
necessary to design and conduct studies to resolve some 
of these issues.
Conclusion
Monitoring of brain function in critically ill patients must 
begin with a careful clinical evaluation. Monitoring 
systems typically look at single variables and there is a 
need to integrate/combine systems in order to obtain a 
full and accurate assessment of the patient’s condition so 
as to be able to select the most appropriate therapy. 
Importantly, neuromonitoring is a dynamic process and 
not a single measurement; the ability to follow changes 
over time is vital to assess response to therapy and 
predict prognosis. No monitor will, by itself, improve 
patient outcomes but wise interpretation of the data and 
integration of the information obtained into an 
individualized therapeutic plan should help optimize care 
of critically ill patients with brain injury.
Key messages
• Monitoring of brain function should be considered in 
all comatose patients in the ICU.
• Brain monitoring is centered on a careful clinical 
examination, although this can be limited in comatose 
and/or sedated patients.
• Th e goals of neuromonitoring are to: identify 
worsening neurological function and secondary insults 
that may beneﬁ t from speciﬁ c treatments; improve 
pathophysiological understanding of cerebral disease 
in critical illness; provide physiological data to guide 
and individualize therapy; assist in prognostication.
• At present there is no ‘ideal’ single brain monitor; a 
combination of monitoring techniques may provide 
better insight into brain function than a single monitor 
used alone.
• Trends over time and threshold values are both 
important when assessing brain function.
• Clinical studies suggest the physiological feasibility 
and biological plausibility of management based on 
information from various monitors but data 
supporting this concept from randomized trials are 
still required.
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